May 21 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it has withdrawn an application seeking approval for its flu and COVID combination vaccine candidate to wait for efficacy data from ...

(Reuters) -Moderna said on Friday it has filed a marketing application for the review of its updated COVID-19 vaccine with the U.S. Food and Drug Administration. The company said the submission for ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Moderna's decision to withdraw ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for ...